Beam Therapeutics' stock dropped 9% after initial phase 1/2 data on BEAM-302 for alpha-1 antitrypsin.
https://seekingalpha.com/news/4419041-beam-drops-9-data-for-genetic-lung-disease-candidate
Beam Therapeutics' stock dropped 9% after initial phase 1/2 data on BEAM-302 for alpha-1 antitrypsin.
https://seekingalpha.com/news/4419041-beam-drops-9-data-for-genetic-lung-disease-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.